Trifluridine
Nucleoside Analog Antiviral — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: 5-Trifluorothymidine, trifluorothymidine
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Trifluridine is an ofp drug in the Nucleoside Analog Antiviral class catalogued in DrugCentral. It was first approved by the FDA in 1980. Its mechanism of action is classified as Nucleic Acid Synthesis Inhibitors. DrugCentral lists 2 molecular targets, including UL23 and tmk. Recorded indications include Herpes simplex keratitis, Herpes simplex keratoconjunctivitis, Malignant tumor of colon and Malignant tumor of stomach.
- Approval status: ofp (first approved 1980 by the FDA).
- Drug class: Nucleoside Analog Antiviral; Nucleoside Metabolic Inhibitor.
- Mechanism of action: Nucleic Acid Synthesis Inhibitors.
- Molecular targets: UL23 and tmk (2 listed in DrugCentral).
- Indications: Herpes simplex keratitis, Herpes simplex keratoconjunctivitis, Malignant tumor of colon and Malignant tumor of stomach.
- ATC code: L01BC59 (Pyrimidine analogues).
- Molecular formula: C10H11F3N2O5; molecular weight 296.20 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (4)
- Herpes simplex keratitis
- Herpes simplex keratoconjunctivitis
- Malignant tumor of colon
- Malignant tumor of stomach
Mechanism & targets
| Mechanism of action (MoA) | Nucleic Acid Synthesis Inhibitors |
|---|---|
| Established pharmacologic class | Nucleoside Analog Antiviral; Nucleoside Metabolic Inhibitor |
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Thymidine kinase | UL23 | unknown | IC50 5.70 |
| Thymidylate kinase | tmk | unknown | Ki 4.01 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2014-03-24 | PMDA | — | Taiho Pharmaceutical Co., Ltd. | Yes |
| 1980-04-10 | FDA | — | MONARCH PHARMS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01BC59 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ANTIMETABOLITES › Pyrimidine analogues |
S01AD02 | SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFECTIVES › Antivirals |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Therapy partial responder | 75.2 |
| Colorectal cancer metastatic | 62.0 |
| Palmar-plantar erythrodysaesthesia syndrome | 53.5 |
| Drug resistance | 47.5 |
| Neutropenia | 44.3 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Trifluridine is on its molecule page.
| Molecular formula | C10H11F3N2O5 |
|---|---|
| Molecular weight | 296.20 g/mol |
| CAS number | 70-00-8 |
| InChIKey | VSQQQLOSPVPRAZ-RRKCRQDMSA-N |
| PubChem CID | 6256 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Trifluridine used for?
DrugCentral lists the following indications for Trifluridine: Herpes simplex keratitis, Herpes simplex keratoconjunctivitis, Malignant tumor of colon and Malignant tumor of stomach.
How does Trifluridine work?
Trifluridine is classified as Nucleic Acid Synthesis Inhibitors; its molecular targets in DrugCentral include UL23 and tmk.
When was Trifluridine first approved?
Trifluridine was first approved by the FDA in 1980.
What drug class does Trifluridine belong to?
Trifluridine is in the Nucleoside Analog Antiviral class.
What is the chemical formula of Trifluridine?
Trifluridine has the molecular formula C10H11F3N2O5 and a molecular weight of 296.20 g/mol.
Browse: all drugs starting with T · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2743 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1129 — compound record and bioactivity
- PubChem CID 6256 — chemical identifiers
- DrugBank DB00432 — drug record
- FDA UNII RMW9V5RW38 — substance identity
- DailyMed: FDA labels for Trifluridine — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.